Conferences: PALACE-2

Pembrolizumab With NCRT Shows No Increased AL Risk in ESCC

Posted by Oncweekly Editor | Aug 26, 2024 | Esophageal Cancer, Gastrointestinal Cancer |

KEY TAKEAWAYS The Phase 2 & 3 trials aimed to assess the impact of pembrolizumab with NCRT on...

Read More

Recent Posts

Proapoptotic Potential of MAC-NCs in Gastric Cancer CellsSeptember 20, 2024
Boron Neutron Capture Therapy for Spinal TumorsSeptember 20, 2024
Venetoclax and Hypomethylating Agents in Coexisting MM and AMLSeptember 20, 2024
New Bioinformatics-Based Model for Cervical Cancer DiagnosisSeptember 20, 2024
Plasma ccfDNA & mtDNA as Biomarkers in Breast CancerSeptember 20, 2024

Recent Comments

No comments to show.